Jul 21, 2014 - 3D-Druck News

Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies

MORGANTOWN, W.V. and SCHLIEREN, Switzerland, July 9, 2014 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) and InSphero AG jointly announced today that they have entered into a collaboration that will combine each company’s respective 3D technology. InSphero AG is the leading supplier of 3D organotypic microtissues for in vitro toxicology and efficacy studies, with models derived from liver, pancreas, tumor, and brain tissue that yield a high level of predictability during drug development compared to traditional 2-dimensional cell culture and other in vitro model systems. The collaboration will use Protea’s proprietary LAESI(R) direct molecular imaging platform to analyze InSphero’s proprietary 3D InSight(TM) microtissues, creating 3D molecular profiles for tissue characterization, drug metabolism and distribution, pharmacokinetic and toxicity applications. From this collaboration, Protea and InSphero expect to create new products and services that may be marketed to pharmaceutical and biotechnology researchers worldwide.
(…weiter auf finance.yahoo.com)




Tags: , , ,

Comments are closed.

Wir setzen für unseren Internetauftritt sog. Cookies ein. Durch Einstellungen in Ihrem Browser können Sie die weitere Verwendung von Cookies deaktivieren. Weitere Informationen zu Cookies finden Sie in unserer Datenschutzerklärung

Die Cookie-Einstellungen auf dieser Website sind auf "Cookies zulassen" eingestellt, um das beste Surferlebnis zu ermöglichen. Wenn du diese Website ohne Änderung der Cookie-Einstellungen verwendest oder auf "Akzeptieren" klickst, erklärst du sich damit einverstanden.

Schließen